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Introduction
Acute kidney injury (AKI) is common and severe in 
critically ill patients, with a reported incidence between 1 
and 30% and mortality between 28 and 90%, depending 
on the deﬁ   nition used. Uchino and colleagues [1] 
reported an incidence of 5.7% and a mortality of 60.3% in 
a recent multicenter study involving nearly 30,000 
critically ill patients. In patients with multiple organ 
failure, AKI is an independent predictor of mortality [2,3].
Th  e pathophysiology of AKI remains poorly under-
stood. However, as renal function is intimately linked to 
organ blood ﬂ   ow, alterations in renal perfusion are 
considered key to the pathophysiology of AKI. Little, 
however, is known about renal perfusion in critically ill 
patients [4] or about its association with AKI. Th  is is 
because methods currently available to assess and monitor 
renal perfusion are either inaccurate or not rapidly 
applicable in routine ICU patients. Th   e physiological gold 
standard to estimate renal plasma ﬂ  ow is the calculation 
of para-amino-hippurate clearance. Unfortunately, this 
technique is inaccurate in the presence of oliguria [4,5]. 
Doppler ultrasound studies have been demonstrated to 
be inaccurate in estimating renal blood ﬂ  ow [6] and only 
provide information about ﬂ   ow in main arteries. In 
addition, all methods only give information about global 
organ perfusion and not about the renal microcirculation 
or on the intra-renal distribution of blood ﬂ  ow.
Imaging methods such as scintigraphy or magnetic 
resonance imaging (MRI) are much more accurate and 
can provide valuable information on kidney perfusion 
[7,8]. However, their use in the ICU is limited by equip-
ment availability, costs and their requirement for exten-
sive and prolonged patient manipulation, which is asso-
ciated with risk and major logistic challenges. Th  ese 
techniques can be used in research protocols but are not 
suitable for routine use in most ICU patients and cannot 
be repeated several times within the same day.
A method allowing reproducible renal perfusion 
quantiﬁ  cation that would be applicable at the bedside, 
and would be minimally invasive or even non-invasive, 
would be ideal in the ICU. Such a method might increase 
our knowledge of the correlation between renal perfusion 
alterations and AKI. It could also potentially help 
clinicians detect patients at risk of renal failure and adapt 
treatment early to prevent AKI.
Abstract
Acute kidney injury (AKI) is common in critically ill 
patients and associated with important morbidity and 
mortality. Although alterations in renal perfusion are 
thought to play a causative role in the pathogenesis 
of AKI, there is, to date, no reliable technique that 
allows the assessment of renal perfusion that is 
applicable in the ICU. Contrast-enhanced ultrasound 
(CEUS) is an ultrasound imaging technique that makes 
use of microbubble-based contrast agents. These 
microbubbles, when injected into the bloodstream, 
allow visualization of vascular structures and, 
with contrast-specifi  c imaging modes, detection 
of blood fl  ow at the capillary level. Some recent 
CEUS-derived approaches allow quantifi  cation of 
blood fl  ow in several organs, including the kidney. 
Current generation ultrasound contrast agents have 
strong stability and safety profi  les. Along with post-
marketing surveillance, numerous studies report safe 
administration of these agents, including in critically 
ill patients. This review presents information on the 
physical principles underlying CEUS, the methods 
allowing blood fl  ow quantifi  cation and the potential 
applications of CEUS in critical care nephrology, 
currently as a research tool but perhaps in the future as 
a way of monitoring renal perfusion.
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Ultrasonography
Ultrasonography is an ultrasound-based diagnostic imag-
ing technique. It relies on the property of sound waves to 
reﬂ  ect at interfaces of media of diﬀ  erent densities as they 
travel through them - the greater the diﬀ  erence in density 
(acoustic impedance), the more echogenic the interface 
[9,10].
Modern ultrasound equipment is portable, reasonably 
cheap and allows bedside examination without requiring 
patient manipulation. Standard ultrasound examinations 
are already performed in the ICU for diagnostic reasons 
(abdominal or liver studies, cardiac echography) and to 
guide interventions (central venous line placement, 
pleural eﬀ  usion drainage). Such equipment is becoming 
widely available and echography is now a standard tech-
nique within most modern ICUs [11].
To evaluate circulation and blood ﬂ  ow, Doppler studies 
can be performed with standard echography equipment. 
Th   e clinical use of Doppler studies is, however, limited by 
the lower limit of detection, its inability to detect slow 
ﬂ  ow velocity and its limited accuracy in quantifying renal 
blood ﬂ   ow. Microbubble-based contrast agents have 
lowered the detection threshold and now allow detection 
of blood in vessels as small as capillaries. Together with 
appropriate imaging modes and modern software, 
contrast-enhanced ultrasonography (CEUS) allows organ 
blood ﬂ  ow quantiﬁ  cation.
Microbubble-based contrast agents
Gases are ideal contrast agents for echography since they 
are highly compressible (17,000 times more than water) 
and since their density is 1,000 times less than the density 
of blood [12]. Embedded within a shell, gases can be 
made to form microbubbles, which are extremely potent 
ultrasound reﬂ  ectors, nine orders of magnitude higher 
than a solid particle of the same size. Th  ese  microbubbles 
change shape when they interact with ultrasound waves, 
contracting during the compression (high pressure) 
phase and expanding during the rarefaction (low pressure) 
phase. At low-intermediate acoustic pressure, these 
microbubble oscillations result in the generation of non-
linear signals [13].
Th  e ﬁ   rst reported echographic contrast agent was 
based on air microbubbles created by agitating saline, 
which was then rapidly injected intravenously. It was 
used to examine the right heart and detect right-to-left 
shunts. Th  e clinical use of agitated saline is, however, 
very limited due to the very short life (a few seconds) of 
air microbubbles and their inability to traverse the 
pulmonary circulation. Safety concerns were also recently 
raised, cerebral ischemic events being reported after use 
of agitated saline, probably related to the broad and 
uncontrolled size distribution of such bubbles [14].
Technological improvements have resulted in the 
develop  ment of small-sized shell-stabilized microbubbles 
with adequate half-life and the capacity to cross the 
pulmo  nary circulation (Figures 1 and 2).
Th  e ﬁ   rst commercially available ultrasound contrast 
agent was Albunex® (Molecular Biosystems, Inc., USA). It 
was obtained by sonicating a 5% human albumin solution 
in the presence of air, resulting in the formation of air 
microbubbles stabilized by a thin denaturated albumin 
shell [15].
Current (second) generation microbubble contrast 
agents make use of inert, poorly soluble perﬂ  uorinated 
gases and are stabilized by phospholipids or albumin [16].
Th   eir half-life in the circulation is a few minutes and the 
perﬂ  uorinated gas present in the microbubbles is totally 
excreted by the lungs [17].
After intravenous injection, microbubbles behave as 
pure blood agents as their size (1 to 6 μm) prevents them 
from diﬀ   using through the endothelium. Th  ey allow 
vascular bed opaciﬁ  cation and have opened the way to 
detecting the microcirculation [18]. Th  e diﬀ  erent com-
mer  cially available ultrasound contrast agents and their 
compositions are detailed in Table 1.
Optimal ultrasound equipment settings
Parallel to the development of eﬃ   cient contrast agents, 
novel imaging modes have been introduced. Harmonic B 
mode, phase or pulse inversion, power modulation, power 
pulse inversion, and coherent pulse sequencing are some 
of the contrast-speciﬁ  c imaging modes (also designated 
as ‘nonlinear’ imaging modes) available in modern ultra-
sound equipment [19]. Based on the non-linear proper-
ties of microbubbles submitted to acoustic pressure, 
these imaging modes use a combination of changes in 
pulse phase and amplitude to selectively minimize tissue 
echoes and enhance ultrasound contrast agent echoes. 
Th   ey all make use of low mechanical index (MI) imaging 
Figure 1. Schematic illustration of a microbubble contrast agent: 
Sonovue (courtesy of Bracco SpA).
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be destroyed when subjected to high acoustic pressures 
(for example, MI >0.7). Th   is unique property is used for 
perfusion quantiﬁ   cation in the so-called destruction 
(ﬂ  ash) reﬁ  lling approach.
Today, contrast-speciﬁ  c modes are available on most 
mid- to high-end ultrasound equipment.
Safety
As for any other drug, ultrasound contrast agents have 
been submitted to extensive clinical investigations both 
for safety and eﬃ   cacy before approval by national health 
authorities.
Since microbubbles of gas are injected into the circu-
lation, legitimate concerns about tissue embolism can be 
raised, especially because, as discussed earlier, initial 
attempts to generate contrast by agitated saline may have 
been associated with embolic events [14]. However, the 
microbubbles in commercial ultrasound contrast agents 
have a much smaller and uniform size than those pro-
duced by agitating saline. Th   ey are also much more stable 
and do not coalesce. Th  erefore, they have a very low 
potential for embolization. Th  is has been conﬁ  rmed by 
intravital microscopy in the cremaster or spinotrapezius 
muscle with diﬀ   erent contrast agents [21-23]. Th  ese 
studies show that the microvascular rheology of ultra-
sound contrast agents is similar to that of red blood cells 
and that microbubble entrapment within the capillaries is 
negligible and transient.
Initial post-marketing surveillance over 5 years and in 
more than 1 million patients has demonstrated no 
medically signiﬁ   cant risk other than allergic events, 
which appear to occur at a rate of approximately 1 per 
10,000 [20]. Central nervous system reactions have also 
been rarely reported and may or may not be associated 
with hypersensitivity reactions. Reported adverse events 
are generally infrequent and mild and may include 
headache, fatigue, palpitations, nausea, dizziness, dry 
mouth, altered sense of smell or taste, dyspnea, urticaria, 
pruritus, back pain, chest pain or rash.
In October 2007, following four deaths in patients with 
severe underlying conditions 1 to 12 hours after injection 
of Deﬁ  nity®, a ‘black box warning’ stating that use of these 
agents was contraindicated in unstable patients was 
released by the US Food and Drug Administration. Th  is 
initiated an intense controversy. Many clinicians still 
Figure 2. Optical microscopic view of microbubbles in rabbit blood (courtesy of Bracco SpA).
Table 1. Commercially available ultrasound contrast 
agents
Contrast
agent Shell  Gas  Registered  in
Optison  Human albumin  Perfl  uoropropane  USA, Canada
Defi  nity   Phospholipids  Perfl  uoropropane  USA, Europe,
(Luminity)       Canada
Sonovue  Phospholipids  Sulfur hexafl  uoride  Canada, Europe, 
     China,  India, 
     Korea
Sonazoid Phospholipids  Perfl   uorobutane  Japan
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safe.
Since then, many studies, including one in a very large 
number of patients, have been published establishing 
CEUS as a safe procedure. For example, Kusnetzky [24] 
demonstrated that the background mortality of patients 
undergoing contrast echography was not signiﬁ  cantly 
higher than that of patients undergoing non-contrast 
echo  cardiography. Dolan and colleagues [25] studied 
42,408 patients from three centers that had received 
contrast agents for either resting or stress echocardio-
graphy and did not ﬁ  nd any diﬀ  erence in mortality or 
adverse events compared to matched controls. A multi-
center registry including 58,254 hospitalized patients that 
underwent echocardiography published by Main and 
colleagues [26] actually showed a decrease in acute mor-
tality compared with patients not receiving contrast 
agent. Wei and colleagues [27] reported a rate of severe 
reactions of 0.01% and no death in 78,383 patients, 
including 10,000 acutely ill patients (either in the ICU or 
with acute chest pain of possible cardiac origin) who had 
received ultrasound contrast agents.
Today, many investigators believe that ultrasound 
contrast agents can be considered safe even in unstable 
patients, even though the Food and Drug Administration 
has not yet withdrawn the black box warning. As for any 
drug or contrast agent, the risk of anaphylactic reaction 
remains present and the use of these products in unstable 
patients should be restricted to centers with full resus-
citation capacities.
As discussed in detail in the next paragraph, blood ﬂ  ow 
quantiﬁ   cation requires use of high MI ultrasound for 
very short periods of time (ﬂ  ashes). Some concerns have 
been raised about the safety of this procedure. Jiménez 
and colleagues [28] showed in a porcine model that 
repeated insoniﬁ  cation of the kidney at high MI did not 
produce any histological change either immediately after 
the procedure or 4 hours later. Th  ere were no signs of 
inﬂ  ammatory response and no signs of extravasation of 
erythrocytes from the capillary system.
Blood fl  ow quantifi  cation by CEUS
Since microbubbles remain conﬁ  ned to the intravascular 
space, and have a rheology similar to that of red blood 
cells, contrast uptake as a function of time can be used to 
estimate quantitative perfusion parameters, such as 
regional blood volume or blood ﬂ  ow.
Theories and methods
Perfusion quantiﬁ   cation by CEUS may be performed 
with a microbubble-destruction technique, introduced in 
1998 by Wei and colleagues [29,30]. Th   is technique was 
validated in a canine model with intermittent imaging 
with destructive frames at increasing imaging frame 
rates, microbubbles being continuously infused by means 
of a syringe pump. Th   is allowed investigators to build a 
curve representing replenishment kinetics from a series 
of clips at diﬀ   erent frame rates. Fitting of this curve 
allows derivation of two relative parameters representing 
perfusion in the tissue: the regional blood volume 
(plateau value) and blood velocity (initial slope of the 
replenishment curve).
Th  e local blood ﬂ  ow, F, is thus the product of micro-
bubble velocity by regional blood volume: F   A  ×  β ,  
where A corresponds to the plateau signal intensity and β 
is the initial slope of the replenishment curve. Although 
these data were derived from the myocardium, the 
authors stated that this method was applicable to any 
tissue accessible to ultrasound.
Th  is technique was later extended to non-destructive 
imaging at low MI with the application of a few destruc  tive 
frames at higher MI to completely destroy the micro-
bubbles in the scan plane [31]. Th  e reperfusion (or re-
plenishment) of microbubbles in the scan plane at low MI 
is recorded as a single clip, and analyzed using the model 
of Wei and colleagues to derive perfusion parameters.
Another formal approach to the estimation of ﬂ  ow, 
developed by Arditi and colleagues [32] for the low MI 
imaging approach, allows improved perfusion estimates 
by considering an echo power signal and taking into 
account the ultrasound beam geometry. Th  is approach 
was recently implemented in the form of a prototype 
software (Bracco Research SpA, Geneva, Switzerland) for 
oﬀ   -line processing of reﬁ   lling sequences. Using this 
software, video data are ﬁ  rst linearized to compute an 
echo-power signal whose amplitude is proportional to 
the local contrast agent concentration. As described in 
the approach by Tiemann and colleagues [31], ﬁ  tting of 
these signals after destruction allows perfusion quanti-
ﬁ  cation. Here, the perfusion parameters considered are: 
relative blood volume (rBV), mean transit time (mTT), 
and blood ﬂ   ow (rBV/mTT) (Figure 3). Th  e software 
further allows the generation of parametric maps, show-
ing the spatial distribution of perfusion parameters at the 
pixel level. Th   is approach establishes a basis for extracting 
information on the perfusion of vascular beds in vivo, 
and allows relative quantiﬁ  cation between selected areas 
of interest, provided that appropriate instrument calibra-
tion is implemented for the data linearization phase.
Clinical applications
Several authors have subsequently used these methods 
and a general good agreement has been reported in 
several organs and tissues.
For example, Rim and colleagues [33] were able to 
quantify cerebral blood ﬂ  ow in dogs at baseline and after 
cerebral blood ﬂ  ow alteration through hypo- or hyper-
capnia. A good correlation was found between A × β 
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by an accepted reference method (radiolabeled 
micro spheres).
Vogel and colleagues [34] were able to quantify myo-
cardial perfusion in humans. In their study, a linear 
correlation was found between myocardial CEUS-
derived parameters and PET perfusion data in healthy 
volunteers at rest (N = 15) and during adenosine-induced 
hyperemia (N = 5). Th  ese investigators also compared 
CEUS with intracoronary Doppler measurements before 
and during intracoronary adenosine injection in patients 
undergoing coronary angiograms and found good agree-
ment with coronary ﬂ  ow velocity reserve.
As far as renal perfusion is concerned, Kishimoto and 
colleagues [35] found a congruent modiﬁ  cation of micro-
circulation with an infusion of dopamine in nine healthy 
subjects. Th  ey subsequently used the same technique 
[36] to study the eﬀ  ect of valsartan on renal perfusion in 
seven healthy volunteers and found a signiﬁ  cant increase 
in microbubble velocity after oral administration of 
valsartan that correlated well with the increase in total 
renal blood ﬂ   ow determined by para-amino-hippurate 
clearance (P < 0.05). In a recently published study, 
Kalantarinia and colleagues [37] tested the utility of 
CEUS to monitor the expected increase in renal blood 
ﬂ  ow after a high protein meal in healthy adults. Th  ey 
found a statistically signiﬁ   cant increase (by 42.8%) in 
renal blood ﬂ   ow (A × β parameter) compared with 
baseline (P = 0.002).
We recently performed a study in ten healthy 
volunteers evaluating changes in the perfusion index (PI; 
a variable that is proportional to blood ﬂ  ow) seen during 
intravenous infusion of angiotensin II and after oral 
captopril. We found a statistically signiﬁ  cant and dose-
dependant decrease in PI during increasing doses of 
angiotensin II compared to baseline. Th   e decreases in PI 
were already detectable when the renal plasma ﬂ  ow (as 
estimated by para-amino-hippurate clearance) decreased 
by 15% [38].
To further illustrate the feasibility of CEUS in the ICU, 
we present the example of a 66-year-old man recently 
studied in our center. Th  is patient had a past medical 
history of non-insulin-dependent diabetes mellitus, 
hyper  tension and hypercholesterolemia. He was com-
plain  ing of chest pain and an angiogram revealed a severe 
triple vessel disease. He was scheduled for an elective 
coronary artery bypass surgery. We performed a renal 
CEUS before and after the operation. Th   e contrast agent 
injections were perfectly tolerated. Th   e images could be 
acquired in less than 15 minutes, including the 
Figure 3. Renal perfusion index measurement using dedicated quantifi  cation software. A screenshot of SonotumorTM, shown as an example 
of software allowing perfusion quantifi  cation in contrast-enhanced ultrasonography sequences. The upper segments show the contrast-enhanced 
images (left) as well as the conventional ultrasound images (right). This is where the reader can draw areas of interest (AOI) that will be analyzed by 
the software. A replenishment curve (lower segment) is then generated for each AOI. These curves represent the intensity of the echo-power as a 
function of time after the fl  ash. Bold lines are fi  tted curves of the actual measured data represented by the clear lines. The fi  tted curves allow the 
derivation of a perfusion index (PI) for each AOI.
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of admission to the ICU. Figure 4 presents some still 
images illustrating the destruction-reﬁ  lling sequences in 
that patient.
Interestingly, we noted a decrease in the perfusion 
indices from a baseline of 10,523 (before the surgery) to 
7,786 (-26.0%; Table 2). Clinically, a transient period of 
oliguria was noted around 12 hours post-surgery and the 
plasma creatinine concentration increased from 79 to 
155 μmol/l (RIFLE F). With adequate ﬂ  uid resuscitation 
and furosemide adminis  tration, the urinary output ﬁ  nally 
normalized but the plasma creatinine concentration 
remained elevated on hospital discharge (121 μmol/l).
Experience in transplant medicine
In renal transplant medicine, a detailed evaluation of 
blood ﬂ   ow in the subcapsular capillaries is highly 
desirable since the latter are primarily involved in acute 
rejection. Fischer and colleagues [39] examined 32 
patients 5 to 7 days after kidney transplantation and were 
able to show that a temporal diﬀ  erence in the contrast 
agent arrival slopes between two main territories allowed 
the diﬀ  erentiation of acute graft rejection from a normal 
clinical course (where the slopes were uniform).
In 26 transplant patients, Schwenger and colleagues 
[40] reported a highly signiﬁ  cant correlation (P = 0.0004) 
between renal blood ﬂ   ow as estimated by CEUS and 
serum creatinine. In the same study, these investigators 
found that the determination of renal blood ﬂ  ow  by 
CEUS reached a higher sensitivity (91 versus 82%), speci-
ﬁ  city (82% versus 64%) and accuracy (85 versus 73%) for 
the diagnosis of chronic allograft nephropathy than 
conventional Doppler ultrasound. Th  ese ﬁ  ndings where 
conﬁ   rmed by Benozzi and colleagues [41], who 
performed CEUS in 39 kidney recipients at 5, 25 and 
30  days after grafting. Th  ese researchers were able to 
show that some CEUS-derived parameters allowed the 
distinc  tion between acute tubular necrosis and acute 
rejection episodes (cortico-medullar ratios of the rBV 
and mTT were lower in the acute tubular necrosis group 
compared to the control group, while another parameter, 
the time to peak, was higher than control in acute 
rejection events).
Perspectives: CEUS in acute kidney injury
CEUS is able to determine and quantify changes in renal 
perfusion and these changes play a role in clinical 
outcome as illustrated by the important ﬁ  ndings  in 
transplant medicine. In the critically ill patient, altera-
tions in renal perfusion are expected to be found in 
various situations, such as septic shock, low cardiac 
output states, hepato-renal syndrome, and hypovolemia. 
However, it is still unclear whether these alterations are 
signiﬁ  cant and related to renal outcome, whether they 
assist in diagnosis and early intervention or whether they 
represent the consequence rather than the cause of 
tubular injury. Given such uncertainty and the need to 
make rapid and repeated measurements early in the 
course of a patient’s illness, CEUS could become an 
impor  tant tool to evaluate and quantify renal perfusion 
alterations in these diﬀ  erent pathologic conditions. More 
importantly, CEUS might enable the study of severity, 
timing, and change over time of renal perfusion as well as 
the intra-renal distribution of perfusion abnormalities. In 
a second step, these observations might help draw a link 
between perfusion abnormalities as shown by CEUS-
derived parameters and AKI, and establish therapeutic 
targets and surrogate markers of adequate renal 
resuscitation. Finally, CEUS could be used to evaluate the 
renal perfusion eﬀ   ect of several of the hemodynamic 
interventions applied to patient care within the ICU.
However, in order to develop and validate this CEUS 
approach (as done in transplant medicine), speciﬁ  cally 
designed studies need to be performed in the setting of 
Figure 4. Example of destruction refi  lling sequences obtained in a 60-year-old male patient 1 hour after coronary artery bypass surgery. 
Each panel of the fi  gure is divided in two; the left side shows contrast specifi  c images and the right side standard B-mode images. (a) After the 
destruction fl  ash (left), no signal is detectable in the contrast-specifi  c image (that is, all the microbubbles have been destroyed). (b) Five seconds 
after destruction (left), partial replenishment of the main arteries with contrast can be noticed. (c) Ten seconds post-destruction (left), the kidney is 
fully replenished with contrast. No signifi  cant changes are observed in B-mode images (a-c, right).
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meters in the main syndromes known to be associated 
with AKI and to develop and validate CEUS-derived 
indices as it was done in transplant medicine. Th  e 
characteristics of CEUS appear to make this approach 
uniquely possible.
CEUS in the ICU
CEUS is particularly well designed for use in the ICU. It 
combines the advantages of being fast, safe, non-invasive 
and repeatedly applicable at the bedside. Second genera-
tion ultrasound contrast agents are safe and well 
tolerated. Th  is should allow repeated scans throughout 
the day to monitor the evolution of renal perfusion and 
response to treatment. Th  e kidney is relatively easy to 
scan in the supine position and obtaining good quality 
images is relatively easy in most ICU patients. Th  e  tech-
nology allowing renal perfusion evaluation is still under 
improvement but our initial experience shows that CEUS 
can detect a 15% decrease in renal blood ﬂ  ow. Th  is  level 
of sensitivity is probably well above the value of changes 
expected to occur during the major hemodynamic 
events/syndrome known to be associated with AKI [4]. 
Th  us, it seems unlikely that false negative examinations 
would occur with this technology.
Conclusion
CEUS is a safe, non-invasive and reliable technique. In 
many ways, it is ideally designed to monitor renal blood 
ﬂ  ow in ICU patients. Studies in renal transplant patients 
have shown its potential utility in clinical practice. Similar 
studies should now be performed in ICU patients to 
determine whether CEUS parameters predict or facilitate 
the early diagnosis of AKI and whether they can help 
assess the impact of therapeutic interventions in real time. 
CEUS would then logically help identify patients at risk of 
AKI at an earlier time and allow clinicians to adapt therapy 
to optimize renal perfusion and perhaps prevent AKI.
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